著者

小畑 友紀雄 出口 粧央里 山口 瑞季 稲葉 一訓 長井 紀章 中田 雄一郎

雑誌

日本薬学会第142年会(名古屋)

巻号頁・発行日

2022-02-01

著者

松田 千恵 大津山 裕美子 須崎 宏子 新田 朋弘 小畑 友紀雄 安原 智久

出版者

一般社団法人 日本医療薬学会

雑誌

日本医療薬学会年会講演要旨集

巻号頁・発行日

vol.24, 2014

著者

中本 賀寿夫 小畑 友紀雄 平澤 明 金 啓二 金 守良 徳山 尚吾

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.136, no.4, pp.583-589, 2016-04-01 (Released:2016-04-01)

参考文献数

41

被引用文献数

2 2

---

Nonalcoholic fatty liver disease (NAFLD) is characterized by the pathological accumulation of fat in the liver in the absence of any other disease related to liver steatosis, which includes a wide spectrum of liver diseases ranging from mild asymptomatic fatty liver to nonalcoholic steatohepatitis (NASH) and cirrhosis. Recently, it was reported that NAFLD is characterized by the impaired bioavailability of liver n-6 and n-3 long-chain polyunsaturated fatty acids (PUFAs). That is, compared with healthy individuals, steatosis and steatohepatitis patients have higher n-6/n-3 PUFA ratios. Furthermore, per recent research, decreasing the intake of total fats and increasing the intake of n-3 PUFAs may be beneficial in the treatment of NAFLD. In contrast, some reports describe that NASH patients have more metabolic abnormalities than NAFLD patients; however, these are not influenced by dietary fatty acids. Thus, at present, various opinions exist regarding the efficacy of n-3 PUFA in the treatment of NAFLD. In this review, we discuss the considerable interest n-3 PUFA has attracted as a potential treatment for NAFLD.